Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Sebban

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|September 13, 2007
[Are antiangiogenic antibodies universal for solid tumor?]Isabelle Ray-Coquard, Thomas Bachelot, Chadi Saba, et al.
Journal of Hematology & Oncology|June 12, 2012
Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphomaAdrien Chauchet, Anne-Sophie Michallet, Françoise Berger, et al.
Blood|February 11, 2003
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Nicolas Mounier, Josette Briere, Christian Gisselbrecht, et al.
Blood|June 16, 2010
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, et al.
The Oncologist|October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphomaAndré Bosly, Andrew Grigg, Harald Holte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study groupFranck Morschhauser, Pauline Brice, Christophe Fermé, et al.
Applied Health Economics and Health Policy|February 26, 2013
Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM TrialLionel Perrier, Anne Lefranc, David Pérol, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2016
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapseGaëlle Fossard, Céline Ferlay, Emmanuelle Nicolas-Virelizier, et al.
Haematologica|June 12, 2013
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trialNicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, et al.
Blood|September 19, 2008
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyGilles Salles, Nicolas Mounier, Sophie de Guibert, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|September 13, 2007
[Are antiangiogenic antibodies universal for solid tumor?]Isabelle Ray-Coquard, Thomas Bachelot, Chadi Saba, et al.
Journal of Hematology & Oncology|June 12, 2012
Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphomaAdrien Chauchet, Anne-Sophie Michallet, Françoise Berger, et al.
Blood|February 11, 2003
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Nicolas Mounier, Josette Briere, Christian Gisselbrecht, et al.
Blood|June 16, 2010
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, et al.
The Oncologist|October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphomaAndré Bosly, Andrew Grigg, Harald Holte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study groupFranck Morschhauser, Pauline Brice, Christophe Fermé, et al.
Applied Health Economics and Health Policy|February 26, 2013
Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM TrialLionel Perrier, Anne Lefranc, David Pérol, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2016
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapseGaëlle Fossard, Céline Ferlay, Emmanuelle Nicolas-Virelizier, et al.
Haematologica|June 12, 2013
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trialNicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, et al.
Blood|September 19, 2008
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyGilles Salles, Nicolas Mounier, Sophie de Guibert, et al.
Pageof 6